May. 4 at 4:54 PM
$PRQR The Biotech Acquisition Playbook
Every major biotech acquisition follows the same quiet pattern before the announcement:
✅ Big Pharma executive joins the board
✅ Authorized shares increased
✅ Explicit “acquisitions & partnerships” language in SEC filings
✅ Heavy investor meeting activity
✅ Clinical data catalyst imminent
✅ Existing Big Pharma partnership already paying milestones
We saw this exact pattern with:
→ Karuna → BMS at
$330/share (53% premium)
→ Prometheus → Merck at
$200/share (75% premium)
→ Mirati → BMS at
$58/share (52% premium)
$PRQR just filed ALL of these signals simultaneously on May 4, 2026.
A sitting Boehringer Ingelheim CMO nominated to the board. Authorized shares increased to 270M. The word “acquisitions” literally written into their SEC filing. AX-0810 Phase 1 data dropping imminently. Active Lilly collaboration worth up to
$3.75B in milestones.
Trading at ~
$1.59with an ve alyst targets of
$8.50–
$14.00.
The pattern is clear. The data is coming. NFA.DYOR.
